DocCheck AG (AJ91) AI Stock Analysis

• Market Cap: €56.88M
• Dividend Yield: 6.36%
• Average Volume (3M): 1.04K
• Price to Earnings (P/E): 9.8
• Beta (1Y): 0.70
• Revenue Growth: 8.24%
• EPS Growth: 140.53%
• Country: DE
• Employees: 373
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.48
• Shares Outstanding: 5,033,876
• 10 Day Avg. Volume: 577
• 30 Day Avg. Volume: 1,041
• PEG Ratio: 0.06
• Price to Book (P/B): 1.06
• Price to Sales (P/S): 0.79
• P/FCF Ratio: 6.21
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 68 Neutral
• Price Target: €13.50 ▲(20.54% Upside)

DocCheck AG's overall stock score is driven by its strong financial performance and attractive valuation. The company's low P/E ratio and high dividend yield are significant positives. However, technical analysis indicates potential short-term weakness, which slightly offsets the overall score.

Positive Factors

Profitability

Strong profitability metrics indicate efficient operations and pricing power, supporting sustained earnings and competitive positioning.

Cash Generation

Robust cash generation enhances financial flexibility, enabling strategic investments and shareholder returns, supporting long-term growth.

Leverage

Conservative leverage reduces financial risk, providing stability and resilience against economic fluctuations, supporting sustainable growth.

Negative Factors

Revenue Decline

A decline in revenue indicates potential market challenges or competitive pressures, which could impact future profitability and market position.

Revenue Growth

Minimal revenue growth suggests limited expansion, which could hinder competitive advantage and market share in a dynamic industry.

Asset Decline

Decreasing assets and equity can limit growth opportunities and financial resilience, potentially affecting long-term strategic initiatives.

DocCheck AG Business Overview & Revenue Model

Company Description

DocCheck AG is a leading provider of online services and solutions tailored specifically for healthcare professionals. Based in Germany, the company operates primarily in the healthcare and medical sectors, offering a range of products that include a professional network for healthcare practitioners, e-learning platforms, and various digital solutions that facilitate communication and information exchange within the medical community.

How the Company Makes Money

DocCheck AG generates revenue through multiple streams, primarily by providing subscription-based access to its professional network and additional services aimed at healthcare professionals. The company offers premium memberships that grant users access to exclusive content, tools, and resources. Additionally, DocCheck earns revenue from advertising and sponsorships on its platform, leveraging its niche audience of healthcare professionals to attract targeted advertisers. Partnerships with pharmaceutical companies and medical organizations also contribute significantly to its earnings by providing sponsored content and educational materials that are of interest to its user base.

DocCheck AG Financial Statement Overview

Summary

DocCheck AG displays solid financial performance with strong profitability and efficient cash flow management. The company maintains a prudent balance sheet with low leverage, although declining revenue and assets pose potential challenges. Continued focus on revenue growth and asset management will be crucial to sustain financial health.

Income Statement

DocCheck AG's income statement shows strong profitability with a gross profit margin of 19.6% and a net profit margin of 9.8% for the latest annual period. Revenue growth has been relatively stable, with a modest increase of 0.7% from the previous year. The EBIT margin improved substantially to 12.0% from 6.6%, indicating enhanced operational efficiency. However, there is a concern over the company's declining total revenue over the last few years, which may impact future profitability.

Balance Sheet

The balance sheet of DocCheck AG reflects a solid financial position with a low debt-to-equity ratio of 0.12, suggesting conservative leverage. The equity ratio stands at 65.9%, indicating a strong equity base relative to total assets. Return on equity is healthy at 13.2%, showcasing efficient use of equity capital. However, declining total assets and stockholders' equity in recent periods may pose potential risks to long-term financial stability.

Cash Flow

The cash flow statement highlights a robust operating cash flow to net income ratio of 1.48, demonstrating strong cash generation relative to net income. Free cash flow increased by 21.3% year-over-year, reflecting effective cash management. The company maintains a positive free cash flow to net income ratio of 1.29, underscoring its ability to generate surplus cash after capital expenditures. Nevertheless, fluctuations in free cash flow over recent years warrant monitoring.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	56.55M	53.79M	53.41M	60.90M	85.92M	63.10M
Gross Profit	13.95M	10.53M	12.97M	14.08M	21.54M	18.26M
EBITDA	11.54M	10.18M	9.38M	13.38M	20.09M	15.90M
Net Income	5.87M	5.28M	2.27M	6.29M	11.40M	9.20M
Balance Sheet
Total Assets	53.98M	60.86M	56.14M	63.28M	60.25M	46.99M
Cash, Cash Equivalents and Short-Term Investments	19.05M	21.02M	17.52M	15.66M	21.52M	19.99M
Total Debt	3.70M	5.01M	5.85M	7.07M	7.03M	1.61M
Total Liabilities	15.25M	20.78M	18.11M	23.86M	22.08M	15.64M
Stockholders Equity	38.73M	40.08M	37.33M	38.57M	37.31M	30.91M
Cash Flow
Free Cash Flow	5.17M	6.82M	5.62M	-557.91K	6.90M	9.15M
Operating Cash Flow	7.31M	7.82M	7.51M	5.89M	10.92M	12.57M
Investing Cash Flow	-2.97M	-1.48M	-1.93M	-4.92M	-4.39M	-936.57K
Financing Cash Flow	-4.90M	-3.50M	-4.60M	-5.81M	-5.86M	-1.08M

DocCheck AG Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 11.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:AJ91, the sentiment is Neutral. The current price of 11.2 is below the 20-day moving average (MA) of 11.42, below the 50-day MA of 11.90, and below the 200-day MA of 11.57, indicating a bearish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 44.01 is Neutral, neither overbought nor oversold. The STOCH value of 35.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:AJ91.

DocCheck AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
M3V	80 Outperform	€44.77M	10.41	24.14%	3.86%	-5.72%	-25.19%
AJ91	68 Neutral	€56.88M	9.77	15.57%	6.36%	8.24%	140.53%
NXU	66 Neutral	€1.23B	36.15	11.97%	0.32%	7.41%	26.99%
COP	60 Neutral	€1.32B	70.92	2.87%	0.20%	1.16%	-43.53%
V3V	55 Neutral	€106.33M	-10.79	-50.39%	―	9.48%	-481.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%